EMA has accepted GW Pharmaceuticals’ request to review the MMA (Marketing Authorisation Application) of Epidiolex, or cannibidiol. The treatment is currently used on patients who suffer from seizures linked to Lennox-Gastaut syndrome and Dravet syndrome. GW Pharmaceuticals first submitted Epidiolex for review in December 2017. The successful filing of the MAA of the drug follows
UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy. The approval follows data from two late-stage trials that showed when Epidiolex was added as an adjunct to patients’ current treatment, there was a significant reduction in the
GW Pharma has released mixed results for the year, with sales rising and profits decreasing, but the company continues to demonstrate potential in their R&D pipeline with inspiring data for a mid-stage, cannaboid-based diabetes drug. The organisation saw their sales for the year ending September 30, 2012, increase by £3.5 million to reach £33.1 million,
